CN115427413A - 磺酰胺类化合物的晶型及其制备方法 - Google Patents

磺酰胺类化合物的晶型及其制备方法 Download PDF

Info

Publication number
CN115427413A
CN115427413A CN202180031074.XA CN202180031074A CN115427413A CN 115427413 A CN115427413 A CN 115427413A CN 202180031074 A CN202180031074 A CN 202180031074A CN 115427413 A CN115427413 A CN 115427413A
Authority
CN
China
Prior art keywords
formula
compound
crystal form
crystal
preparation
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202180031074.XA
Other languages
English (en)
Inventor
鲁霞
钟智
张晓宇
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Crystal Pharmatech Co Ltd
Original Assignee
Crystal Pharmatech Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Crystal Pharmatech Co Ltd filed Critical Crystal Pharmatech Co Ltd
Publication of CN115427413A publication Critical patent/CN115427413A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Dermatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

本发明涉及磺酰胺类化合物的晶型及其制备方法。本发明提供了式（I）化合物的五种晶型B、C、D、E、F及其制备方法和用途。本发明还提供晶型A的制备方法。本发明提供的式（I）化合物晶型B、C、D、E、F，在溶解度、熔点、稳定性、溶出度、引湿性、黏附性、流动性、生物有效性以及加工性能、提纯作用、制剂生产、安全性等方面中的至少一方面上存在优势，为含式（I）化合物的药物制剂的制备提供了新的更好的选择，对于药物开发具有非常重要的意义。
Figure DEST_PATH_IMAGE002
式（I）。

Description

PCT国内申请，说明书已公开。

Claims (20)

  1. PCT国内申请，权利要求书已公开。
CN202180031074.XA 2020-04-27 2021-04-27 磺酰胺类化合物的晶型及其制备方法 Pending CN115427413A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN2020103470860 2020-04-27
CN202010347086.0A CN113637018A (zh) 2020-04-27 2020-04-27 磺酰胺类化合物的晶型及其制备方法
PCT/CN2021/090151 WO2021218948A1 (zh) 2020-04-27 2021-04-27 磺酰胺类化合物的晶型及其制备方法

Publications (1)

Publication Number Publication Date
CN115427413A true CN115427413A (zh) 2022-12-02

Family

ID=78373342

Family Applications (2)

Application Number Title Priority Date Filing Date
CN202010347086.0A Withdrawn CN113637018A (zh) 2020-04-27 2020-04-27 磺酰胺类化合物的晶型及其制备方法
CN202180031074.XA Pending CN115427413A (zh) 2020-04-27 2021-04-27 磺酰胺类化合物的晶型及其制备方法

Family Applications Before (1)

Application Number Title Priority Date Filing Date
CN202010347086.0A Withdrawn CN113637018A (zh) 2020-04-27 2020-04-27 磺酰胺类化合物的晶型及其制备方法

Country Status (5)

Country Link
US (1) US20230203040A1 (zh)
EP (1) EP4144737A4 (zh)
JP (1) JP2023523786A (zh)
CN (2) CN113637018A (zh)
WO (1) WO2021218948A1 (zh)

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MA38347A1 (fr) 2013-02-22 2017-10-31 Pfizer Dérivés de pyrrolo[2,3-d]pyrimidine en tant qu'inhibiteurs de janus kinases (jak)
AU2019299666B2 (en) 2018-07-06 2024-07-11 Pfizer Inc. Manufacturing process and intermediates for a pyrrolo(2,3- d)pyrimidine compound and use thereof
WO2020088659A1 (en) * 2018-11-01 2020-05-07 Lynk Pharmaceuticals Co. Ltd. Tricyclic janus kinase 1 inhibitors, and compositions and methods thereof
WO2020261041A1 (en) * 2019-06-27 2020-12-30 Glenmark Life Sciences Limited Process for preparation of abrocitinib

Also Published As

Publication number Publication date
EP4144737A1 (en) 2023-03-08
WO2021218948A1 (zh) 2021-11-04
JP2023523786A (ja) 2023-06-07
EP4144737A4 (en) 2023-12-13
US20230203040A1 (en) 2023-06-29
CN113637018A (zh) 2021-11-12

Similar Documents

Publication Publication Date Title
US11014925B2 (en) Co-crystals of 1-(4-fluoro-phenyl)-4-((6bR,1OaS)-3-methyl-2,3,6b,9,10,10a-hexahydro-1H,7H- pyrido[3′,4′:4,51_pyrrolo [1,2,3-delqcuinoxalin-8-yl)-butan-1-one with nicotinamide or isonicotinamide
CN110494423B (zh) 乐伐替尼甲磺酸盐的新晶型及其制备方法
TW202115093A (zh) Ｃｆｔｒ調節劑之結晶形式
EP3122753A2 (en) Ibrutinib solid forms and production process therefor
EP3436455A1 (en) Novel salts and crystals
AU2017373239B2 (en) Crystalline forms of a bromodomain and extraterminal protein inhibitor drug, processes for preparation thereof, and use thereof
TW202220962A (zh) 選擇性NaV抑制劑的結晶形式及其製備方法
WO2021129589A1 (zh) Kd-025的新晶型及其制备方法
CN117417263A (zh) Rad1901-2hcl的多晶型形式
WO2016127844A1 (zh) IPI-145的晶型α及其制备方法
TW201617347A (zh) 一種ｊａｋ激酶抑制劑的硫酸氫鹽的結晶形式及其製備方法
WO2021000687A1 (zh) Pac-1晶型的制备方法
WO2020061996A1 (zh) 氘代azd9291化合物的新晶型及其用途
WO2020244348A1 (zh) 呋喃并咪唑并吡啶类化合物的合成方法、呋喃并咪唑并吡啶类化合物的晶型及其盐的晶型
WO2023193563A1 (zh) 一种噻吩并吡啶化合物的晶型a、制备方法及其药物组合物
CA3051146A1 (en) Crystal form of gft-505 and preparation method and use thereof
CN115427413A (zh) 磺酰胺类化合物的晶型及其制备方法
CN116802183A (zh) 二氮杂双环类化合物的对甲苯磺酸盐新晶型及其制备方法
US20220098206A1 (en) Solid state forms of oclacitinib maleate
CN108570045B (zh) 氢溴酸山莨菪碱的晶型、其制备方法、药物组合物
CN114026088A (zh) Jak2抑制剂的结晶形式
CN112272667A (zh) 盐形式
WO2018177276A1 (zh) 一种微管蛋白抑制剂的a晶型
CN112262138A (zh) 盐形式
EP1813602A1 (en) Crystal of two-ring heterocyclic sulfonamide compound

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
CB03 Change of inventor or designer information

Inventor after: Lu Xia

Inventor after: Zhang Xiaoyu

Inventor after: Zhong Zhi

Inventor before: Lu Xia

Inventor before: Zhong Zhi

Inventor before: Zhang Xiaoyu

CB03 Change of inventor or designer information